Revumenib in Combination With 7+3 + Midostaurin in AML
Revumenib in Combination With 7+3 + Midostaurin in AML
Recruiting · NCT06313437 · Registry updated 2026-03-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Revumenib in Combination With 7+3 + Midostaurin in AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-03-25 | NCT06313437 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Richard Stone, MD | 2 |
| Syndax Pharmaceuticals | 16 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Yale Cancer Center | New Haven | United States | 1 |